

#### **Innovating Surface Protection Products to Reduce the Spread of Pathogens**

Committed to Making Lives Safer



JANUARY 2025

#### Forward-Looking Statement

This presentation contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; expectations regarding industry trends, including with respect to the antimicrobial surface and coating market, sponge market, overall market growth rates and the Company's growth rates and growth strategies; that microbe repellent technology is a promising, high-growth industry; the use of available funds; the performance of the Company's business and operations; the Company's expectations regarding revenues, expenses and anticipated cash needs; the intention to grow the Company's business, product pipeline and operations, including exploring and completing acquisitions and licensing opportunities; the expected timing and completion of the Company's near-term objectives; the eco-sponge opportunity, benefits, key differentiators, and synergies; completion of signing of a definitive agreement to acquire certain IP and trademarks and enter into a supply agreement for the eco-sponge/foam pads pursuant to the LOI with Scott smith and US BioSolutions; laws and regulations and any amendments thereto applicable to the Company; the Company's competitive advantages and business and growth strategies; the expected development, timing and achievement of the Company's future product offerings, including potential new applications (i.e. catheters) and new formulations (i.e. spray), the proposed eco-spongeproducts and other applications; the intention to explore development opportunities using the eco-foam pad in skin drug delivery; the Company's research and development initiatives and expected results thereof; the Company's growing patent portfolio; the Company entering into distribution, licensing, royalty, manufacturing and other business relationships, in Canada, the United States, and globally for its REPELWRAP<sup>m</sup> film, spray, catheter coating or other products including the eco-sponge; the household sponge market offering significant opportunity for the eco-sponge; the potential of the Company's technology to protect against the spread of pathogens on surfaces through repelling bacteria and viruses that come in contact with its surface; that the Company's technology will bring significant value in controlling the spread of surface borne infectious diseases; trends regarding healthcare-acquired infections and antibiotic resistant pathogens; the Company's ability to access multi-million-dollar markets for any of its proposed products; proprietary REPELWRAP<sup>™</sup> film and/or spray could be used on high-touch surfaces such as bed rails, doorknobs, and medical devices to help prevent pathogen transmission; the Company's nanotechnology has the potential to be applied to other types of surfaces and materials - such as catheters which could significantly help reduce blockages caused by bacterial colony and/or blood clot formation in long-use catheters, if the Company can successfully adapt their technology; the Company's intention to initially target REPELWRAP<sup>m</sup> film towards healthcare settings and high traffic public touchpoints; that as the Company continues its product development, we may see it used to protect surfaces in other high traffic places like the transportation, education. sports and entertainment sectors; the growing global commitment to reduce the spread of pathogens; the timing and development of the Company's spray nanotechnology, including plans to enter into pilot scale-up upon completion of formulation, which could be easier to apply to many surfaces and expand potential market applications; the Company's organic growth strategy and expansion strategy; line extensions for REPELWRAP<sup>™</sup> film; timing and development of a nano-coating for catheters, and further development of core technology as well as into additional applications; expansion into vertical markets; access and receipt of non-dilutive funding; the achievement of revenues from any product through sales, licensing or distribution agreements; licensing or acquisition of additional nanotechnology formulations and/or complementary products that reduce pathogen spread; potential licensing, M&A and partnerships within the infectious disease space: and that REPELWRAP<sup>M</sup> film and/or spray will provide additional protection to current disinfecting practices to control the spread of pathogens.

Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history, no revenues and uncertainty around additional financing; negative cash flow history; no production history and lack of revenues from sales; no history of manufacturing or distribution; highly competitive industry; satisfying the terms of the License Agreement, Spray License Agreement and Collaborative Research Agreements between the Company and McMaster University and maintaining licenses in good standing; inability of McMaster University to satisfy the terms under the License Agreement, Spray License Agreement and Collaborative Research Agreements; ability to successfully complete scale-up and development of commercial film, spray or other products; ability to successfully complete real-world environmental testing of REPELWRAP<sup>m</sup> film; research and development activities; reliance on grant funding; limited number of products; dependence on collaborative partners, licensors and others; no formal manufacturing, licensing or distribution agreements in place; no certainty of completion of acquisition of IP and trademark and entry into supply agreement for eco-sponge pursuant to LOI with Scott Smith and US BioSolutions; no certainty of entering into formal distribution agreement with Sinelabs pursuant to LOI: changes and restrictions due to legal and regulatory requirements: dependence on each product's acceptance in the market; possibility of smaller market opportunities than anticipated: increasing regulatory and compliance costs for public companies; global economic instability; product liability claims and lawsuits; system failures; reliance on management and loss of key employees or inability to hire key personnel; limited experience of senior management in managing a public company; fraudulent or illegal activity by employees, contractors and consultants; inability to effect service of process on some of the Company's directors and officers; management's efforts and abilities; potential conflicts of interest; inability to protect intellectual property rights; inability to secure patents or grow its patent portfolio; infringement on proprietary rights of third parties; risks related to forward-looking information; volatility of the market price of the Company's common shares; potential dilution of the common shares; lack of an active, liquid and orderly trading market for the common shares; failure of securities or industry analysts to publish research or publish inaccurate or unfavourable research about the Company; inability or unwillingness to pay dividends; exchange rate fluctuations between the Canadian dollar and the U.S. dollar; effect of COVID-19 public health crisis or another global health pandemic; use of available funds; effect of general economic and political conditions; internal controls; and other risk factors set forth in the Company's public filings, publicly available through the Canadian Securities Administrators' SEDAR+ website at www.sedarplus.ca. The reader is urged to refer to the Company's other public filings, publicly available through SEDAR+ at www.sedarplus.ca for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any Forward-looking statements contained in this presentation are expressly qualified in their entirety by this cautionary statement.

While the information contained in this presentation is believed to be accurate, the Company expressly disclaims any and all liability for any losses, claims or damages of whatsoever kind based upon the information contained in, or omissions from, this presentation or any oral communication transmitted in connection therewith. In addition, none of the statements contained in this presentation are intended to be, nor shall be deemed to be, representations or warranties of the Company. Where the information is from third-party sources, the information is from sources believed to be reliable, but the Company has not independently verified any of such information contained herein.

This presentation is not, and under no circumstances is to be construed as, a prospectus, an offering memorandum, an advertisement or a public offering of securities. Under no circumstances should the information contained herein be considered an offer to sell or a solicitation of an offer to buy any securities.





#### ADVANCING NOVEL TECHNOLOGIES FOR EFFECTIVE PATHOGEN CONTROL

- Nanotechnology\*: developing film & spray formats that repel pathogens, keeping surfaces clean, and nano-coating of catheters
- <u>Eco-Friendly Sponge</u>\*\*: sustainable, reusable sponge for cleaning surfaces and for development as a drug delivery device in wound care market
- Acquisition/Licensing: exploring additional innovative technologies to enhance our current portfolio to reduce pathogen spread

\* Licensed from McMaster University \*\*LOI signed with Scott Smith and US BioSolutions for supply eco-friendly sponge







## Silent Pandemic: The Alarming Reality of Pathogens

- Rise of antibiotic-resistant (AMR) pathogens is a growing global healthcare threat, posing significant healthcare and economic issues
- 1.27 M deaths globally attributed to AMR in 2019<sup>1</sup>
- AMR could surpass cancer as leading cause of death by 2050<sup>2</sup>
- ~US\$1 trillion additional global healthcare costs by 2050<sup>1</sup>
- US\$1 trillion \$3.4 trillion global GDP losses / year by 2030<sup>1</sup>





Sources:

1. Antimicrobial resistance

2. https://www.medscape.com/viewarticle/amr-could-surpass-cancer-leading-cause-death-2050-2024a1000lvr?\_gl=1\*1vitkn4\*\_gcl\_au\*MTQyNTg0NTc4OC4xNzM3MTQ0MTQw&form=fpf



#### **AMR: Hidden Threats in Everyday Places**





### **Current Hygiene Practices:** Failing to Halt the Rise of AMR

- Over-prescribing and misuse of antibiotics accelerates the development of resistance
- Improper or inconsistent cleaning can facilitate their transmission

Additional innovative solutions are needed to contribute to reducing the spread of AMR pathogens





## Novel Eco-Friending Sponge for Surface Cleaning and Skin Drug Delivery

- LOI to acquire IP and BioFoam® trademark, and enter into a supply agreement for eco-friendly sponge to clean surfaces and as a drug delivery device in would care market <sup>1</sup>
- Technology currently used to detect / remove oil and contamination from water
- Synergist opportunity to enhance FendX's current product development portfolio to keep surfaces clean



## Prototype eco-friendly sponge



<sup>1</sup> IP refers to certain patent applications for use. Supply agreement will allow for use of open-cell technology and trade secrets held by vendors.

# Household Sponge Market Offers Significant Opportunity for Eco-Friendly Sponge

#### Estimated North American sponge market revenue in 2033 (USD)<sup>1</sup>

~\$2.9 Bn

~ 4.5% CAGR (2024-2033)

Sources: 1. <u>https://www.astuteanalytica.com/industry-report/north-america-household-cleaner-sponge-market</u>

#### Key Differentiators of the Eco-Friendly Sponge:

- Innovative Technology: resistant to bacterial growth and odors vs. traditional sponges
- Sustainable: washable and reusable for long-term
   use
- Biodegradable: degrades over time under anaerobic conditions, i.e., landfills
- Porous Structure: absorbs cleaning agent, reducing amount needed for cleaning vs. traditional sponges
- Inert Surface: Does not alter functionality of certain cleaning products (i.e., quat compounds found in Lysol and Clorox) vs. traditional sponges



### **Eco-Friendly Sponge: Skin Drug Delivery Use**

- FDA 501(k) approved skin lotion impregnated in sponge to protect against chemical burns
- Cleared based on studies conducted by the U.S. Department of the Army



 PCT filed entitled: Open-Cell Foam Based Wound Treatment - to be acquired by FendX pursuant to LOI





### Unique Nanotechnology to Protect Surfaces

Provides immediate & continuous protection of surfaces reducing adhesion of bacteria and virus >98%<sup>1,2,3</sup>

When a contaminated hand touches a nano-coated protected surface, the contamination tends to stay on the hand and not transfer to the surface<sup>1,2,3</sup>

\*Nanotechnology licensed from McMaster University

Sources:

- 1. https://pubs.acs.org/doi/10.1021/acsami.1c21476?ref=pdf
- 2. https://pubs.acs.org/doi/10.1021/acsami.3c11074
- 3. https://pubs.acs.org/doi/10.1021/acsami.2c23119?ref=pdf





Schematic illustration comparing transfer of viruses from common high-touch surfaces from a contaminated hand.

## <sup>\*</sup>**REPELWRAP<sup>™</sup> Film**

#### Lead Nano-Coated Product in Development

- >98% reduction in adhesion of a Covid-19 like virus, E. coli, B. subtilis and MRSA<sup>1,2</sup>
- Target markets: healthcare and other high-touch, high traffic venues (i.e., transportation, schools)
- Manufacturing scale-up confirmed with Dunmore\*

CSE: FNDX | OTCQB: FDXTF | FSE:E8D

 In field testing to assess efficacy and durability in realworld environments

## Adhesive backing to easily apply to high touch surfaces



Sources:

1. https://pubs.acs.org/doi/10.1021/acsami.1c21476?ref=pdf

2. https://pubs.acs.org/doi/10.1021/acsami.3c11074





\* Dunmore International Corp. ("Dunmore"), a Steel Partners Holdings L.P. (NYSE:SPLP) operating company is a globally recognized film manufacturer.

### **Nano-Particles Spray Coating**

#### Offers Additional Approach to Applying a Surface Protection Coating

- 99.9% reduction in MRSA and Pseudomonas aeruginosa and 98% for Phi6 (a virus)<sup>1</sup>
- Expected to be easier to apply and expand applications
- Completing formulation work and will transfer formulation to nanoComposix\* for scale-up



Schematic illustration of nanoparticle suspension



 \* nanoComposix LLC, a Fortis Life Science Company ("nanoComposix")

1. https://pubs.acs.org/doi/10.1021/acsami.2c23119?ref=pdf



## <sup>\*</sup>REPELWRAP<sup>™</sup> Film and Nano-Particle Suspension Competitive Landscape

	REPELWRAP™ Film & Spray*	Liquid Disinfectants	Metal- Containing** and Photo-Activated Films
<b>Repels</b> bacteria, viruses, blood and liquids	+++	-	-
Instantly protects	+++	+++	+
24-hour protection	+++	-	+++
<b>Does not promote</b> bacterial resistance	+++	+	+

\* Based on McMaster testing of REPELWRAP<sup>™</sup> film lab prototype (ACS Appl. Mater. Interfaces 2022, 14, 11068-11077; ACS Nano. 2020 Jan 28, 14 (1) 454-465; 3) \*\* Silver, copper, zinc



## Antimicrobial & Antiviral Nano-Coating: A Significant Opportunity

Estimated global market revenue in 2031 (USD)<sup>1</sup>



~ 8% CAGR (2024-2031)

Sources: 1. https://www.futuremarketsinc.com/the-global-market-for-antimicrobial-antiviral-and-antifungal-nanocoatings-2021/



FendX has signed LOI with Sinelabs who will distribute FendX future film & spray in overlapping target market





### **Nano-Coating Foley Catheters**

**In Development to Reduce Infections** 



#### Estimated global market revenue in 2033 (USD)<sup>1</sup>

## ~\$2.6 Bn

~ 5.4% CAGR (2023-2033)

 ~1 M foley catheter-associated infections at medical cost US\$0.3-\$2.3 Bn <sup>2,3</sup>

- >96% reduction in attachment of E. coli after 24-48 hours of flow exposure <sup>4</sup>
- In prototype development

Sources:

- 1. Foley Catheter Market Size, Outlook & Growth Report 2033
- 2. https://https://pmc.ncbi.nlm.nih.gov/articles/PMC8992741/
- 3. www.infectioncontroltoday.com/view/new-iv-guidelines-whats-most-critical-know
- 4. https://onlinelibrary.wiley.com/doi/abs/10.1002/smll.202108112





### **Building A Robust Nano-Tech Patent Portfolio**

Omniphobic Surfaces with Hierarchical Structures, and Methods of Making and Uses Thereof

- Chinese/ Macau Patent # ZL 202080055337.6 granted
- US Patent Application # 17/616,374 granted
- Japan Patent Application # 2021-572059 granted
- Hong Kong Patent Application # 62022061224.1 granted
- Macao Patent Application # ZL 202080055337.6 granted
- Canada Patent Application # CA3142127
- Europe Patent Application # EP20819372.2

#### **Omniphobic Antimicrobial Microparticles and Compositions Thereof**

• US Provisional Patent Application No 63/415078

#### Methods of Making Omniphobic Materials with Hierarchical Structures and Uses Thereof

- US Patent Application Number # 18/683,578
- Canada Patent Application # CA3228893
- China Patent Application # CN202280056197.3
- Europe Patent Application # EP22857186.5
- Japan Patent Application pending

#### Fluorine-free Superhydrophobic Surfaces, Methods of Making and Uses Thereof

- US Patent Application # 18/683,559
- Canada Patent Application # CA3228891
- China Patent Application # CN202280056201.6
- Europe Patent Application # EP22857178.2
- Japan Patent Application pending



#### Capital Light Model



Partner with contract manufacturers

LOI signed for Eco-friendly sponge supply agreement



Secure licensing/distribution partners; FendX signed LOI with Sinelabs who will distribute FendX future products in overlapping target market



As corporate sponsor, support McMaster in securing grants for FendX projects





#### **FendX Share Structure**

#### Share Structure as of December 31, 2024

Shares outstanding:	73,448,359
Options:	5,741,667
RSUs	593,334
Warrants:	18,954,320

Insider ownership < 20%





#### **Proven Management Team**



Dr. Carolyn Myers MBA, PhD President, CEO & Director

- Accomplished senior pharma executive with extensive experience in creating, leading and growing health care businesses
- Principal of BioEnsemble LLC, advising start-ups and small pharma companies in developing their business strategy and planning
- Previously, Vice President International Business Development and Alliance Management at Allergan PLC (market cap \$83 Bn, 2017, now Abbvie); President of Dey Laboratories and President of Mylan Technologies Inc. (market cap \$9.2 Bn, 2011, now Viatris Inc.)



Rose Zanic CPA, CA CFO & Corporate Secretary

- Over 25 years of capital markets and corporate finance expertise
- Significant experience advising Canadian public companies with financing, M&A transactions and providing public company administration.
- Previously Senior Vice-President, Corporate Finance at Wolverton Securities Ltd.
- Experience as a director and/or officer with several Canadian publicly listed companies
- Member of the TSX Venture Exchange BC Local Advisory Committee



Tash Yousuf BSc Sr. Operations Manager

- Expertise in project and operations management
- Oversees business operations and product development, driving FendX's key projects forward
- Software Project Coordinator at Lenbrook International
- Operations Manager at Cineplex VIP
   Cinemas





### **Board of Directors**

Stephen Randall CPA, CGA Independent Board Member & Audit Committee Chair	<ul> <li>Senior financial manager and Director with over 40 years' experience.</li> <li>Served in senior financial roles with both private, publicly traded and start-up companies in the manufacturing, telecommunications, technology, and medical device sectors.</li> <li>Former Board Member, CFO and Corporate Secretary of Titan Medical Inc (TSX: TMD and NASDAQ: TMDI)</li> </ul>
Pierre Soulard B.C.L., LLB, LLM Independent Board Member	<ul> <li>Former Chief Legal Officer of CoinSmart (NEO: SMRT)</li> <li>Former partner, at Miller Thomson, a leading Canadian law firm.</li> <li>Focused on securities law, corporate finance, mergers and acquisitions and corporate governance for a wide range of national and international issuers and investors.</li> </ul>

Dr. Carolyn Myers MBA, PhD Board Member







#### **Advisors**

#### Scott Smith Advisor

- CEO and founder of US BioSolutions and the innovator of BioFoam® technology and trade secrets
- Winner of Blueprint's 2024 Impact Award for Positive Social Change
- Inventor named on 25 patents for testing/remediation of water, surfaces, and air contaminated with dangerous pathogens, excess nutrients/harmful algal blooms and related toxins, oil, chemicals, and metals
- · Holds degrees from Baylor University and Harvard Business School
- Recognized with the United States Small Business Administration Phoenix Award for Small Business Disaster Recovery
- Has been to more than 75 different oil and chemical disasters in the US and abroad

#### Dr. Tohid Didar Advisor

- Awarded the University Scholar title in 2024
- Canada Research Chair in NanoBiomaterials
- Associate Professor in the Department of Mechanical Engineering, School of Biomedical Engineering and a
  member of the Institute of Infectious Disease Research at McMaster University
- Co-inventor of REPELWRAP™ film
- Expert in biomedical devices, bio-sensing, microfluidics, bio-functional interfaces and bio-hybrid micro/nano robots
- · Postdoctoral fellow at Wyss Institute at Harvard University





### **Company Highlights**

- Focused on developing products in the infectious disease control area to protect surfaces from bacteria and viruses
- REPELWRAP<sup>™</sup> film, FendX's lead product in development, is in real-world beta-testing to confirm its repelling properties
- LOI to acquire certain IP rights and supply agreement to use eco-friendly sustainable & reusable sponge for use in healthcare, consumer and medical markets
- Nano-particle suspension product (spray) in formulation phase and upon completion will enter pilot scale-up

- Catheters coated with FendX's nanotechnology in prototype development to reduce blood clot and bacterial biofilm formation
- FendX actively seeking in-licensing/acquisition opportunities to add innovative technologies to build comprehensive infection control product and IP portfolio
- Robust IP portfolio with 5 granted patents
- Strong leadership team with experience creating, leading and growing successful businesses



## **Thank You!**



investor@fendxtech.com / fendxtech.com

